After Astellas Pharma (ALPMF) and Poseida Therapeutics (PSTX) announced that Xyphos Biosciences, a wholly owned subsidiary of Astellas, and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR programs by combining the cell therapy platforms from each of the companies, William Blair analyst Sami Corwin said the firm views the additional collaboration “favorably” as it will provide additional non-dilutive capital, further validates Poseida’s platform and allows the company “to foray into the universal CAR space.” The firm has an Outperform rating on Poseida shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics Strikes Major CAR-T Therapy Collaboration Deal
- Poseida Therapeutics management to meet with Piper Sandler
- Poseida Therapeutics Shares Genetic Medicine R&D Insights
- Poseida Therapeutics files to sell 8.33M shares of common stock for holders
- Poseida Therapeutics Unveils Cancer Research Breakthroughs at AACR